Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma

Silvia Pelligra,Natalia Buza,Pei Hui,Stefania Bellone,Burak Zeybek,Elena Ratner,Peter E. Schwartz,Giovanni Scambia,Alessandro D. Santin

Gynecologic Oncology Reports（2020）

引用 4|浏览44

暂无评分

摘要

•Uterine serous carcinoma is an aggressive variant of endometrial cancer overexpressing HER2.•Heterogeneity in HER2/neu expression is detected in over 50% of USC.•Chemotherapy plus Trastuzumab is the preferred regimen for advanced HER2 USC.•Selection of HER2-negative tumors could be a mechanism-of-resistance to Trastuzumab.

查看译文

关键词

Trastuzumab,HER2/neu,Uterine serous carcinoma,Recurrent,Treatment-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要